Charles C Wykoff Selected Research

Retinal Vasculitis

3/2024	Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry.
1/2024	Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting.
11/2023	Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
1/2023	RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence.
1/2022	Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
1/2022	MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
1/2017	Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis: Clinical Characteristics of 36 Eyes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles C Wykoff Research Topics

Disease

50	Macular Degeneration (Age-Related Maculopathy) 03/2024 - 03/2013
50	Macular Edema 12/2023 - 01/2013
41	Diabetic Retinopathy (Retinopathy, Diabetic) 11/2023 - 07/2014
13	Retinal Vein Occlusion 09/2023 - 09/2014
11	Inflammation (Inflammations) 03/2024 - 01/2018
9	Geographic Atrophy 04/2024 - 01/2020
7	Retinal Vasculitis 03/2024 - 01/2017
7	Endophthalmitis (Ophthalmia) 09/2023 - 04/2011
7	Retinal Detachment (Retinal Detachments) 10/2022 - 01/2021
6	Atrophy 04/2024 - 01/2013
6	Hypoxia (Hypoxemia) 01/2022 - 06/2002
5	Retinal Perforations 01/2023 - 01/2010
4	Cataract (Cataracts) 07/2023 - 09/2010
4	Retinal Diseases 01/2023 - 01/2011
4	Ischemia 10/2022 - 01/2013
4	Edema (Dropsy) 01/2018 - 12/2014
3	COVID-19 01/2023 - 10/2020
3	Choroidal Neovascularization 05/2021 - 01/2016
3	Diabetes Mellitus 01/2021 - 06/2018
2	Choroidal Effusions 03/2024 - 01/2018
2	Cysts 01/2024 - 11/2017
2	Disease Progression 10/2023 - 02/2013
2	Blister (Bulla) 09/2023 - 01/2022
2	Central Serous Chorioretinopathy 11/2022 - 01/2009
2	Microaneurysm 11/2021 - 01/2017
2	Vascular Diseases (Vascular Disease) 01/2021 - 01/2020
2	Hypersensitivity (Allergy) 01/2020 - 01/2011
2	Neoplasms (Cancer) 05/2013 - 06/2002
1	Retinal Artery Occlusion 11/2023
1	Polypoidal Choroidal Vasculopathy 11/2022
1	Eye Diseases (Eye Disease) 01/2020
1	Uveitis 08/2019
1	Epilepsy (Aura) 02/2018
1	Stroke (Strokes) 01/2018
1	Myocardial Infarction 01/2018
1	Retinitis Pigmentosa (Pigmentary Retinopathy) 12/2017

Drug/Important Bio-Agent (IBA)

45	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2024 - 01/2011
43	Retinaldehyde (Retinal)IBA 03/2024 - 02/2013
32	afliberceptIBA 11/2023 - 07/2014
27	Ranibizumab (Lucentis)FDA Link 09/2023 - 03/2013
16	Fluorescein (Funduscein)FDA LinkGeneric 10/2022 - 01/2013
12	brolucizumabIBA 03/2024 - 12/2018
11	Biomarkers (Surrogate Marker)IBA 02/2024 - 10/2019
6	Endothelial Growth FactorsIBA 09/2023 - 05/2017
5	salicylhydroxamic acid (SHAM)IBA 10/2023 - 01/2017
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2024 - 05/2017
4	Angiopoietin-2IBA 12/2023 - 01/2019
4	faricimabIBA 12/2023 - 01/2019
4	pegcetacoplanIBA 10/2023 - 01/2020
4	CytokinesIBA 06/2023 - 01/2021
4	N-acetyltryptophanamide (NATA)IBA 01/2023 - 12/2014
4	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 01/2021 - 01/2018
4	Fluocinolone Acetonide (Capex)FDA LinkGeneric 11/2020 - 01/2017
3	Complement System Proteins (Complement)IBA 11/2023 - 01/2022
2	Complement C3 (C3 Complement)IBA 11/2023 - 01/2020
2	PlacebosIBA 10/2023 - 10/2023
2	abicipar pegolIBA 01/2023 - 01/2020
2	Verteporfin (Visudyne)FDA Link 11/2022 - 01/2009
2	SuspensionsIBA 01/2021 - 01/2018
2	Povidone-Iodine (Betadine)FDA LinkGeneric 01/2020 - 01/2011
2	SteroidsIBA 01/2018 - 01/2009
2	Anti-Bacterial Agents (Antibiotics)IBA 07/2016 - 11/2011
2	Transcription Factors (Transcription Factor)IBA 10/2004 - 07/2004
2	Proteins (Proteins, Gene)FDA Link 06/2003 - 12/2002
1	SDDSIBA 04/2024
1	formycin diphosphate (FDP)IBA 01/2023
1	Vascular Endothelial Growth FactorsIBA 01/2023
1	Vascular Endothelial Growth Factor CIBA 01/2023
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 11/2022
1	Neurofibromin 2 (Merlin)IBA 01/2022
1	Capsules (Microcapsules)IBA 01/2022
1	Pentosan Sulfuric Polyester (Pentosan Polysulfate)FDA Link 01/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021
1	Complement Inactivating AgentsIBA 01/2021
1	AngiopoietinsIBA 01/2021
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020
1	IodineIBA 01/2020
1	Mydriatics (Cycloplegics)IBA 10/2019
1	frovatriptan (Allegro)FDA Link 02/2018
1	SiliconIBA 11/2017
1	Hemoglobins (Hemoglobin)IBA 09/2017
1	Vancomycin FDA LinkGeneric 01/2017

Therapy/Procedure

28	Therapeutics 11/2023 - 05/2013
17	Injections 03/2024 - 07/2014
12	Vitrectomy 03/2024 - 01/2010
12	Lasers (Laser) 10/2023 - 02/2013
9	Intravitreal Injections 09/2023 - 04/2011
7	Light Coagulation 10/2023 - 01/2017
4	Retreatment 10/2023 - 01/2018
2	Traction 04/2024 - 01/2022
2	Scleral Buckling 07/2022 - 01/2022
2	Vitreoretinal Surgery 01/2022 - 10/2020
2	Operative Surgical Procedures 01/2021 - 06/2017
1	Transplantation 09/2023
1	Cryotherapy (Therapy, Cold) 01/2021
1	Visual Prosthesis 12/2017
1	Glycemic Control 09/2017
1	Drug Therapy (Chemotherapy) 05/2017